ArticleScientific reports2025
Comprehensive evaluation of risk factors for LNM and distant metastasis in patients with NSCLC.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Intensity- and time-dependent anticancer effects of alternating electric fields in non-small cell lung cancer cell lines.Oncology letters · 2026Article
- Prognostic significance of fibroblast senescence and senescence-associated secretory phenotype factor expression in the tumor microenvironment of pancreatic ductal adenocarcinoma.Oncology reports · 2026Article
- [Advances in Antibody-drug Conjugates for Non-small Cell Lung Cancer after Resistance to First-line Therapy].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Metastasis in non-small cell lung cancer (NSCLC) significantly impacts patient recurrence and survival outcomes. Despite its importance, the factors influencing NSCLC metastasis are not fully understood. This study aimed to explore the association between demographic factors, gene mutation status, and EGFR exon mutation status with NSCLC metastasis, utilizing data from a large cohort of NSCLC patients. This study included a cohort of 1,217 NSCLC patients who received treatment at the First Affiliated Hospital of Chongqing Medical University between December 2019 and November 2023. Comprehensive demographic and clinicopathological data were collected. Mutation status in 9 driver genes and 7 EGFR exon sites were identified. Chi-square or Fisher's exact tests were utilized to examine the associations between these factors and NSCLC metastasis. Logistic regression analysis was conducted to determine the factors influencing metastasis. Among the 1,217 NSCLC patients, 536 (44.0%) experienced lymph node metastasis, and 426 (35.0%) had distant metastasis. A history of smoking emerged as an independent risk factor for lymph node metastasis (OR = 1.79, P = 0.01), with higher T stages correlating with an increased risk of lymph node involvement. Compared to squamous cell carcinoma, adenocarcinoma (OR = 1.95, P < 0.01) and other histological subtypes (OR = 3.62, P < 0.01) were identified as independent risk factors for distant metastasis. RET gene mutation (Mutant vs. Wild-type) was an independent risk factor for distant metastasis (OR = 3.05, P = 0.01). After adjusting for various factors, the Exon 21-L858R mutation (Mutant vs. Wild-type) was independently associated with a lower risk of lymph node metastasis (OR = 0.55, P = 0.002).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.